Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial...
11 insider purchases on record · latest filing 2023-06-09.
Insiders have also filed 1 sale transaction at NBIO.